Chiu Ada W, Contreras Sofia, Mehta Sangeeta, Korman Jennifer, Perreault Marc M, Williamson David R, Burry Lisa D
1 Peace Arch Hospital, Fraser Health Authority, White Rock, British Columbia, Canada.
2 Hospital Universitari de Bellvitge, L'Hospitalet de Llobretat, Barcelona, Spain.
Ann Pharmacother. 2017 Dec;51(12):1099-1111. doi: 10.1177/1060028017724538. Epub 2017 Aug 9.
To (1) provide an overview of the epidemiology, clinical presentation, and risk factors of iatrogenic opioid withdrawal in critically ill patients and (2) conduct a literature review of assessment and management of iatrogenic opioid withdrawal in critically ill patients.
We searched MEDLINE (1946-June 2017), EMBASE (1974-June 2017), and CINAHL (1982-June 2017) with the terms opioid withdrawal, opioid, opiate, critical care, critically ill, assessment tool, scale, taper, weaning, and management. Reference list of identified literature was searched for additional references as well as www.clinicaltrials.gov .
We restricted articles to those in English and dealing with humans.
We identified 2 validated pediatric critically ill opioid withdrawal assessment tools: (1) Withdrawal Assessment Tool-Version 1 (WAT-1) and (2) Sophia Observation Withdrawal Symptoms Scale (SOS). Neither tool differentiated between opioid and benzodiazepine withdrawal. WAT-1 was evaluated in critically ill adults but not found to be valid. No other adult tool was identified. For management, we identified 5 randomized controlled trials, 2 prospective studies, and 2 systematic reviews. Most studies were small and only 2 studies utilized a validated assessment tool. Enteral methadone, α-2 agonists, and protocolized weaning were studied.
We identified 2 validated assessment tools for pediatric intensive care unit patients; no valid tool for adults. Management strategies tested in small trials included methadone, α-2 agonists, and protocolized sedation/weaning. We challenge researchers to create validated tools assessing specifically for opioid withdrawal in critically ill children and adults to direct management.
(1)概述重症患者医源性阿片类药物戒断的流行病学、临床表现及危险因素;(2)对重症患者医源性阿片类药物戒断的评估与管理进行文献综述。
我们使用术语“阿片类药物戒断”“阿片类药物”“鸦片制剂”“重症监护”“重症患者”“评估工具”“量表”“逐渐减量”“撤机”及“管理”检索了MEDLINE(1946年至2017年6月)、EMBASE(1974年至2017年6月)和CINAHL(1982年至2017年6月)。对已识别文献的参考文献列表以及www.clinicaltrials.gov进行了检索以获取更多参考文献。
我们将文章限制为英文且涉及人类的研究。
我们识别出2种经过验证的儿科重症阿片类药物戒断评估工具:(1)戒断评估工具版本1(WAT - 1)和(2)索菲亚戒断症状观察量表(SOS)。这两种工具均未区分阿片类药物戒断和苯二氮䓬类药物戒断。WAT - 1在重症成人患者中进行了评估,但未被证实有效。未识别出其他成人工具。对于管理,我们识别出5项随机对照试验、2项前瞻性研究和2项系统评价。大多数研究规模较小,仅有2项研究使用了经过验证的评估工具。对肠内美沙酮、α - 2激动剂和规范化撤机进行了研究。
我们识别出2种适用于儿科重症监护病房患者的经过验证的评估工具;未发现适用于成人的有效工具。在小规模试验中测试的管理策略包括美沙酮、α - 2激动剂和规范化镇静/撤机。我们呼吁研究人员开发专门用于评估重症儿童和成人阿片类药物戒断的经过验证的工具,以指导管理。